Vous êtes ici

Variabilité des symptômes chez les patients atteints de BPCO

P.-R. Burgel*, C. Arveiller-Carvallo, P. Chanez

Références


[1] Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global stra tegy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;187:347-65.

[2] Rodriguez-Roisin R. Toward a consensus defi nition for COPD exacerbations. Chest 200 0;117:398S-401S.

[3] Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal- Singer R, et al. Susce ptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128-38.

[4] Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect o f exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-22.

[5] Kessler R, Partridge MR, Miravitlles M, Cazzola M, Vogelmeier C, Leynaud D, et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Resp J 2011;37:264-72.

[6] Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, et al. Changes in fo rced expiratory volume in 1 second over time in COPD. N Engl J Med 2011;365:1184-92.

[7] Van den Berge M, Hop WC, Van der Molen T, Van Noord JA, Creemers JP, Schreurs AJ, e t al. Prediction and course of symptoms and lung function around an exacerbation in chronic obstructive pulmonary disease. Respir Res 2012;13:44.

[8] Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obst ructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin 2009;25:2043-8.

[9] Sumner H, Woodcock A, Kolsum U, Dockry R, Lazaar AL, Singh D, et al. Predictors of objective cough frequency in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;187:943-9.

[10] Spengler CM, Shea SA. Endogenous circadian rhythm of pulmonary function in healthy humans. Am J Respir Crit Care Med 2000;162:1038-46. [11] Gonzalez Rodriguez E, Hernandez A, Dibner C, Koehler Ballan B, Pechère-Bertschi A. Arterial blood pressure circadian rhythm: signifi cance and clinical implications. Rev Med Suisse 2012;8:1709-12.

[12] Marsh SE, Travers J, Weatherall M, Williams MV, Aldington S, Shirtcliffe PM, et al. Proportional classifi cations of COPD phenotypes. Thorax 2008;63:761-7.

[13] Burgel PR, Nesme-Meyer P, Chanez P, Caillaud D, Carré P, Perez T, et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest 2009;135:975-82.

[14] Hansel NN, McCormack MC, Belli AJ, Matsui EC, Peng RD, Aloe C, et al. In-home air p ollution is linked to respiratory morbidity in former smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;187:1085-90.

[15] Osman LM, Douglas JG, Garden C, Reglitz K, Lyon J, Gordon S, et al. Indoor air qual ity in homes of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;176:465-72.

[16] Bernstein AS, Rice MB. Lungs in a warming world: climate change and respiratory hea lth. Chest 2013;143:1455-9.

Auteurs correspondants


*Auteur correspondant.
Adresse e- mail : pierre-regis.burgel@cch.aphp.fr (P.-R. Burgel).

Auteurs


P.-R. Burgel1*, C. Arveiller-Carvallo2, P. Chanez3

1Pneumologie, Hôpital Cochin, AP-HP, 27 rue du Faubourg-Saint-Jacques, 75679 Paris Cedex 14
2Service de pneumologie, Hôpital Foch, 40 rue Worth, 92151 Suresnes
3Activités ambulatoires Thorax, Hôpital Nord, AP-HM,chemin des Bourrelly, 13015 Marseille

Liens d'intérêts


  • P.-R. Burgel : Board, conseil (Almirall, Novartis, Nycomed) ; Actions de formation, conferences (AstraZeneca; Boerhinger- Ingelheim, Pfi zer, Nycomed, Novartis, GSK, Chiesi).
  • C. Arveiller-Carvallo : aucun.
  • P. Chanez : P. Chanez a fourni des activités de conseil (Almirall, BI, Centocor, GSK, MSD, AZ, Novartis, Teva, Chiesi, Schering Plough) ; a siégé aux comités consultatifs (Almirall, BI, Centocor, GSK, AZ, Novartis, Teva , Chiesi, Schering Plough, MSD) ; a reçu des honoraires de conférencier (Almirall, BI, Centocor, GSK, AZ, Novartis, Teva, Chiesi, Schering Plough, MSD) ; a reçu des subventions (Almirall, Boston BI scientifi que, Centocor, GSK, AZ, Novartis, Teva, Chiesi, Schering Plough).